Skip to main content

Table 1 Patient characteristics

From: Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

  CAB with GnRH antagonist CAB with GnRH agonist  
n = 34 n = 50 P-value
Median age at diagnosis years (range) 75(50–88) 74 (55–85) 0.09†
 ≥ 75 years old (%)   19 (56) 22 (44) 0.28‡
Median pretreatment PSA level ng/mL (range)   176.4 (51.5–5076) 136.4 (51.9–5827) 0.82†
Pathological diagnosis Gleason score 6 1 2 0.78‡
Gleason score 7 9 8
Gleason score 8 11 21
Gleason score 9 11 16
Gleason score10 2 3
No of Gleason score 8–10 (%)   24(70) 40(80) 0.19‡
T category T2 4 9 0.60‡
T3 24 33
T4 6 7
Unknown 0 1
Bone metastasis EOD0 16 22 0.72‡
EOD1 7 9
EOD2 8 10
EOD3 3 6
EOD4 0 1
Unknown 0 2
Lymph node metastasis (%) Positive 21 (62) 25 (50) 0.58‡
Negative 13 (38) 23 (46)  
Unknown 0 2  
When to use bicalutamide Concurrently 15 12  
Before 19 38  
Median observation period days (range)   761 (212–1529) 1141(175–3419) < 0.01*
  1. †: Wilcoxon’s rank sum test, ‡: Chi-square test, *: Log-rank test
  2. CAB combined androgen blockade, EOD the extent of disease, GnRH gonadotropin-releasing hormone, PSA prostate-specific antigen
  3. EOD stratification
  4. EOD grade 0; normal and benign bone disease
  5. EOD grade 1; number of bone metastases < 6
  6. EOD grade 2; number of bone metastases 6–20
  7. EOD grade 3; number of bone metastases > 20 but less than “super scan”
  8. EOD grade 4; super scan